ERIC ROHREN to Positron-Emission Tomography
This is a "connection" page, showing publications ERIC ROHREN has written about Positron-Emission Tomography.
Connection Strength
4.024
-
Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. AJR Am J Roentgenol. 2016 Mar; 206(3):623-31.
Score: 0.453
-
Qualitative FDG PET Image Assessment Using Automated Three-Segment MR Attenuation Correction Versus CT Attenuation Correction in a Tertiary Pediatric Hospital: A Prospective Study. AJR Am J Roentgenol. 2015 Sep; 205(3):652-8.
Score: 0.437
-
PET/Computed Tomography and Patient Outcomes in Melanoma. PET Clin. 2015 Apr; 10(2):243-54.
Score: 0.422
-
Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality. J Nucl Med Technol. 2011 Jun; 39(2):83-90.
Score: 0.325
-
F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review. Clin Nucl Med. 2011 Feb; 36(2):96-100.
Score: 0.318
-
DOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination. Clin Nucl Med. 2022 Feb 01; 47(2):174-175.
Score: 0.171
-
Spectrum of Benign Bone Conditions on NaF-PET. Semin Nucl Med. 2017 07; 47(4):392-396.
Score: 0.122
-
Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016 Apr; 41(4):268-73.
Score: 0.114
-
Comparison of Standardized Uptake Values in Normal Structures Between PET/CT and PET/MRI in a Tertiary Pediatric Hospital: A Prospective Study. AJR Am J Roentgenol. 2015 Nov; 205(5):1094-101.
Score: 0.111
-
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12.
Score: 0.108
-
Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015 Aug; 56(8):1177-84.
Score: 0.108
-
Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. JAMA Oncol. 2015 May; 1(2):253-5.
Score: 0.107
-
The acetabular fossa hot spot on 18F-FDG PET/CT: epidemiology, natural history, and proposed etiology. Skeletal Radiol. 2015 Jan; 44(1):107-14.
Score: 0.103
-
Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):906-14.
Score: 0.098
-
(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013 Dec; 40(12):1809-16.
Score: 0.095
-
Reporting guidance for oncologic 18F-FDG PET/CT imaging. J Nucl Med. 2013 May; 54(5):756-61.
Score: 0.093
-
PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012 Apr; 198(4):902-8.
Score: 0.086
-
False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol. 2012 Mar; 198(3):W304-14.
Score: 0.086
-
Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant? Acad Radiol. 2012 May; 19(5):535-41.
Score: 0.085
-
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
Score: 0.085
-
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010 Oct 01; 116(19):4487-94.
Score: 0.078
-
Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. J Appl Clin Med Phys. 2010 Feb 04; 11(1):3073.
Score: 0.074
-
The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15; 115(22):5184-92.
Score: 0.073
-
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11.
Score: 0.071
-
An International Survey of PET/CT Clinical Reporting. J Nucl Med. 2019 Apr; 60(4):478-479.
Score: 0.035
-
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Curr Radiopharm. 2018; 11(2):147-152.
Score: 0.032
-
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10(4):449-54.
Score: 0.022
-
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60.
Score: 0.021
-
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
Score: 0.019
-
Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44.
Score: 0.019
-
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8.
Score: 0.019
-
Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009 Jun; 10(6):606-14.
Score: 0.018
-
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009 Mar; 50(3):340-7.
Score: 0.017